# A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

> **NCT05933577** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1089 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Intismeran autogene
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05933577
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-19
- **Primary completion:** 2029-10-26
- **Final completion:** 2030-09-26
- **Target enrollment:** 1089 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933577, "A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05933577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*